Skip to content

EBITDA margin at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
15%+1.8pp
Veracyte logo
VeracyteVCYT
18.3%+8.1pp
Personalis, Inc. logo
Personalis, Inc.PSNL
-143.7%-918pp
NeoGenomics logo
NeoGenomicsNEO
-5.3%-85.9pp
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
-25.5%+32.9pp
GeneDx Holdings logo
GeneDx HoldingsWGS
-9%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Calculated from Castle Biosciences’s reported figures.

Based on trailing twelve months.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's EBITDA margin?
Castle Biosciences (CSTL) reported EBITDA margin of -5.4% in Q1 2026.
How has Castle Biosciences's EBITDA margin changed year-over-year?
Castle Biosciences's EBITDA margin decreased by 165.4% year-over-year, from 8.2% to -5.4%.
What is the long-term trend for Castle Biosciences's EBITDA margin?
Over 5 years (2020 to 2025), Castle Biosciences's EBITDA margin has grown at a -42.8% compound annual growth rate (CAGR), from -9.7% to -0.6%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.